Gyermekkori központi idegrendszeri daganatok érú jdonképzõdés-gátló kezelésének magyarországi eredményei a Kieran-sémával

Translated title of the contribution: Antiangiogenic treatment of pediatric CNS tumors in Hungary with Kieran schedule

P. Hauser, Vancsó Ildikó, Pócza Tímea, D. Schuler, M. Garami

Research output: Contribution to journalArticle

Abstract

In Hungary a new oral antiangiogenic treatment was introduced in cases of primary chemoresistant or recurrent pediatric CNS tumors, called Kieran schedule. The early results of this treatment were analyzed. From 2010 at Semmelweis University on individual decisions a daily combined per oral treatment was introduced in pediatric patients with recurrent or progressive CNS tumor (Kieran schedule: thalidomid, celecoxib, etoposid and cyclophosphamid). Efficacy of therapy was analyzed in terms of demographic data, histology, side effects and tolerability in a retrospective manner. From 2010 through 2013, twenty patients were treated with Kieran schedule (medulloblastoma: 3, ependymoma: 5, anaplastic astrocytoma: 2, GBM: 4, plexus choroideus carcinoma: 1, central primitive neuroectodermal tumor: 1, optic glioma: 2, brainstem tumor: 2). Median treatment time and median progression-free survival were 0.60 and 0.61 years, respectively. Based on the preliminary analysis of a limited cohort of patients, the therapy was efficient in those cases of medulloblastoma, ependymoma, high-grade and optic gliomas, where the expected survival time was more than 3 months at start of treatment. Side effects were slight myelosuppresion in terms of previous therapy, 16% transient ischemic attack (TIA)-like episodes. During therapy patients could live their everyday life. Kieran schedule was well-tolerable and efficient with good quality of life in certain cases of pediatric CNS tumors.

Original languageHungarian
Pages (from-to)259-263
Number of pages5
JournalMagyar Onkologia
Volume57
Issue number4
Publication statusPublished - 2013

Fingerprint

Hungary
Appointments and Schedules
Pediatrics
Neoplasms
Optic Nerve Glioma
Ependymoma
Medulloblastoma
Therapeutics
Celecoxib
Brain Stem Neoplasms
Primitive Neuroectodermal Tumors
Choroid Plexus
Transient Ischemic Attack
Astrocytoma
Disease-Free Survival
Histology
Quality of Life
Demography
Carcinoma
Survival

ASJC Scopus subject areas

  • Oncology
  • Medicine(all)

Cite this

Gyermekkori központi idegrendszeri daganatok érú jdonképzõdés-gátló kezelésének magyarországi eredményei a Kieran-sémával. / Hauser, P.; Ildikó, Vancsó; Tímea, Pócza; Schuler, D.; Garami, M.

In: Magyar Onkologia, Vol. 57, No. 4, 2013, p. 259-263.

Research output: Contribution to journalArticle

@article{b1fac582e4e5483bad9ff085cbaedcb4,
title = "Gyermekkori k{\"o}zponti idegrendszeri daganatok {\'e}r{\'u} jdonk{\'e}pz{\~o}d{\'e}s-g{\'a}tl{\'o} kezel{\'e}s{\'e}nek magyarorsz{\'a}gi eredm{\'e}nyei a Kieran-s{\'e}m{\'a}val",
abstract = "In Hungary a new oral antiangiogenic treatment was introduced in cases of primary chemoresistant or recurrent pediatric CNS tumors, called Kieran schedule. The early results of this treatment were analyzed. From 2010 at Semmelweis University on individual decisions a daily combined per oral treatment was introduced in pediatric patients with recurrent or progressive CNS tumor (Kieran schedule: thalidomid, celecoxib, etoposid and cyclophosphamid). Efficacy of therapy was analyzed in terms of demographic data, histology, side effects and tolerability in a retrospective manner. From 2010 through 2013, twenty patients were treated with Kieran schedule (medulloblastoma: 3, ependymoma: 5, anaplastic astrocytoma: 2, GBM: 4, plexus choroideus carcinoma: 1, central primitive neuroectodermal tumor: 1, optic glioma: 2, brainstem tumor: 2). Median treatment time and median progression-free survival were 0.60 and 0.61 years, respectively. Based on the preliminary analysis of a limited cohort of patients, the therapy was efficient in those cases of medulloblastoma, ependymoma, high-grade and optic gliomas, where the expected survival time was more than 3 months at start of treatment. Side effects were slight myelosuppresion in terms of previous therapy, 16{\%} transient ischemic attack (TIA)-like episodes. During therapy patients could live their everyday life. Kieran schedule was well-tolerable and efficient with good quality of life in certain cases of pediatric CNS tumors.",
keywords = "Antiangiogenesis, Antitumoral treatment, CNS tumor, Pediatric, Recurrence",
author = "P. Hauser and Vancs{\'o} Ildik{\'o} and P{\'o}cza T{\'i}mea and D. Schuler and M. Garami",
year = "2013",
language = "Hungarian",
volume = "57",
pages = "259--263",
journal = "Magyar Onkologia",
issn = "0025-0244",
publisher = "Akademiai Kiado",
number = "4",

}

TY - JOUR

T1 - Gyermekkori központi idegrendszeri daganatok érú jdonképzõdés-gátló kezelésének magyarországi eredményei a Kieran-sémával

AU - Hauser, P.

AU - Ildikó, Vancsó

AU - Tímea, Pócza

AU - Schuler, D.

AU - Garami, M.

PY - 2013

Y1 - 2013

N2 - In Hungary a new oral antiangiogenic treatment was introduced in cases of primary chemoresistant or recurrent pediatric CNS tumors, called Kieran schedule. The early results of this treatment were analyzed. From 2010 at Semmelweis University on individual decisions a daily combined per oral treatment was introduced in pediatric patients with recurrent or progressive CNS tumor (Kieran schedule: thalidomid, celecoxib, etoposid and cyclophosphamid). Efficacy of therapy was analyzed in terms of demographic data, histology, side effects and tolerability in a retrospective manner. From 2010 through 2013, twenty patients were treated with Kieran schedule (medulloblastoma: 3, ependymoma: 5, anaplastic astrocytoma: 2, GBM: 4, plexus choroideus carcinoma: 1, central primitive neuroectodermal tumor: 1, optic glioma: 2, brainstem tumor: 2). Median treatment time and median progression-free survival were 0.60 and 0.61 years, respectively. Based on the preliminary analysis of a limited cohort of patients, the therapy was efficient in those cases of medulloblastoma, ependymoma, high-grade and optic gliomas, where the expected survival time was more than 3 months at start of treatment. Side effects were slight myelosuppresion in terms of previous therapy, 16% transient ischemic attack (TIA)-like episodes. During therapy patients could live their everyday life. Kieran schedule was well-tolerable and efficient with good quality of life in certain cases of pediatric CNS tumors.

AB - In Hungary a new oral antiangiogenic treatment was introduced in cases of primary chemoresistant or recurrent pediatric CNS tumors, called Kieran schedule. The early results of this treatment were analyzed. From 2010 at Semmelweis University on individual decisions a daily combined per oral treatment was introduced in pediatric patients with recurrent or progressive CNS tumor (Kieran schedule: thalidomid, celecoxib, etoposid and cyclophosphamid). Efficacy of therapy was analyzed in terms of demographic data, histology, side effects and tolerability in a retrospective manner. From 2010 through 2013, twenty patients were treated with Kieran schedule (medulloblastoma: 3, ependymoma: 5, anaplastic astrocytoma: 2, GBM: 4, plexus choroideus carcinoma: 1, central primitive neuroectodermal tumor: 1, optic glioma: 2, brainstem tumor: 2). Median treatment time and median progression-free survival were 0.60 and 0.61 years, respectively. Based on the preliminary analysis of a limited cohort of patients, the therapy was efficient in those cases of medulloblastoma, ependymoma, high-grade and optic gliomas, where the expected survival time was more than 3 months at start of treatment. Side effects were slight myelosuppresion in terms of previous therapy, 16% transient ischemic attack (TIA)-like episodes. During therapy patients could live their everyday life. Kieran schedule was well-tolerable and efficient with good quality of life in certain cases of pediatric CNS tumors.

KW - Antiangiogenesis

KW - Antitumoral treatment

KW - CNS tumor

KW - Pediatric

KW - Recurrence

UR - http://www.scopus.com/inward/record.url?scp=84899617999&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899617999&partnerID=8YFLogxK

M3 - Article

C2 - 24353991

AN - SCOPUS:84899617999

VL - 57

SP - 259

EP - 263

JO - Magyar Onkologia

JF - Magyar Onkologia

SN - 0025-0244

IS - 4

ER -